MOLECULAR HAEMATOPATHOLOGY
TEST NAME |
SPECIMEN / REQUIREMENT |
|
mL |
Remarks |
|
|
||
Factor V Leiden mutation screening |
3 |
EDTA PB |
Prothrombin G20210A mutation screening |
3 |
EDTA PB |
Methylenetetrahydrofolate reductase gene C677T mutation screening |
3 |
EDTA PB |
C282Y & H63D mutation of HFE gene |
3 |
EDTA PB |
α-thalassaemia genotyping |
||
α0-thalassaemia test 1 |
3 |
EDTA PB |
α+-thalassaemia test 2 - [-α3.7 ] |
3 |
EDTA PB |
α+-thalassaemia test 3 - [-α4.2 ] |
3 |
EDTA PB |
α-thalassaemia test 4 - [α-globin gene DNA sequencing] |
3 |
EDTA PB |
α-thalassaemia test 5 - [Hb Constant Spring/Hb Quong Sze] |
3 |
EDTA PB |
β-thalassaemia genotyping |
||
β-thalassaemia test - [β-globin gene DNA sequencing] |
3 |
EDTA PB |
Hereditary Persistence of Fetal Haemoglobin screening [HPFH-6 and HPFH-SEA] and Chinese Gγ (Aγδβ)0 thalassaemia |
3 |
EDTA PB |
Myeloproliferative Neoplasms (MPNs) |
||
JAK2 tyrosine kinase gene Val617Phe Mutation Screening |
3 |
Fresh EDTA BM (preferable) / PB |
CALR exon 9 mutation test (test not accredited) |
3 |
Fresh EDTA BM (preferable) / PB |
MPL exon 10 mutation test (test not accredited) |
3 |
Fresh EDTA BM (preferable) / PB |
FIP1L1/PDGFRA derived from an interstitial deletion on chromosome 4q12 by RT-PCR |
3 |
Fresh EDTA BM (preferable) / PB |
ETV6-PDGFRB (TEL-PDGFRB) derived from CMML / MDS with t(5;12)(q33;p13) by RT-PCR |
3 |
Fresh EDTA BM (preferable) / PB |
ZMYM2-FGFR1 (ZNF198-FGFR1) derived from PhNEG myeloproliferative neoplasm with t(8;13) by RT-PCR |
3 |
Fresh EDTA BM (preferable) / PB |
KMT2A-AFF1 (MLL-AF4) derived from ALL with t(4;11)(q21;q23) |
3 |
Fresh EDTA BM (preferable) / PB |
TCF3-PBX1 (E2A-PBX1) derived from ALL with t(1;19)(q23;p13) |
3 |
Fresh EDTA BM (preferable) / PB |
ETV6-RUNX1 (TEL/AML1) derived from ALL with t(12;21)(p13;q22) |
3 |
Fresh EDTA BM (preferable) / PB |
BCR/ABL e1a2 derived from ALL with t(9;22)(q34;q11) |
3 |
Fresh EDTA BM (preferable) / PB |
RUNX1-RUNX1T1 (AML1-ETO) derived from AML with t(8;21)(q22;q22) by RT-PCR |
3 |
Fresh EDTA BM (preferable) / PB |
CBFB/MYH11 derived from AML with inv(16)(p13;q22), t(16;16)(p13;q22) by RT-PCR |
3 |
Fresh EDTA BM (preferable) / PB |
KMT2A-MLLT3 (MLL-AF9) derived from AML with t(9;11)(p22;q23) by RT-PCR |
3 |
Fresh EDTA BM (preferable) / PB |
KMT2A-MLLT10 (MLL-AF10) derived from AML with t(10;11)(p12;q23) by RT-PCR |
3 |
Fresh EDTA BM (preferable) / PB |
PML/RARA derived from AML with t(15;17)(q22;q21) by RT-PCR |
3 |
Fresh EDTA BM (preferable) / PB |
FLT3-ITD mutation screening |
3 |
Fresh EDTA BM (preferable) / PB |
FLT3-TKD D835/I836 mutation test (test not accredited) |
3 |
Fresh EDTA BM (preferable) / PB |
NPM1 mutation test |
3 |
Fresh EDTA BM (preferable) / PB |
CEBPA mutation test (test not accredited) |
3 |
Fresh EDTA BM (preferable) / PB |
BCR/ABL (e13a2 & e14a2) derived from CML with t(9;22)(q34;q11) by RT-PCR |
3 |
Fresh EDTA BM (preferable) / PB |
BCR/ABL1 Quantitative RT-PCR (e13a2 & e14a2 transcript) |
Fresh EDTA PB (3 x 3 ml) |
|
Lymphoproliferative Disorders |
||
BRAF V600E mutation test |
3 |
Fresh EDTA BM (preferable) / PB |
MYD88 L265P mutation test |
3 |
Fresh EDTA BM (preferable) / PB |
KIT exon 8 and 17 mutation (test not accredited) |
3 |
Fresh EDTA BM (preferable) / PB |
BCR/ABL1 kinase domain mutation (test not accredited) |
Fresh EDTA PB (3x3 mL) |
|
MYH9 mutation screening (Exon 17, 27, 31, 39, 41) (test not accredited) |
3 |
EDTA PB |
HLA Markers for Adverse Drug Reactions |
||
HLA-B*15:02 for carbamazepine prescription |
3 |
EDTA PB |
HLA-B*58:01 for allopurinol prescription |
3 |
EDTA PB |
HLA-DQB1*0602 for diagnosis of narcolepsy |
3 |
EDTA PB |
Fluorescence In-situ Hybridization (FISH) Detection of Gene Fusion/Rearrangement |
||
BCR-ABL1 |
Fresh EDTA BM (preferable) / PB |
|
PML-RARA |
||
RUNX1-RUNX1T1 (AML1-ETO) |
||
ETV6-RUNX1 (TEL-AML1) |
||
KMT2A (MLL) rearrangement |
||
4q12 rearrangement |
||
PDGFRB rearrangement |
||
Trisomy 8 |
||
Monosomy 7 |
||
Sex-mismatch (XY) FISH |
||
Multiple myeloma panel: CDKN2C deletion, CKS1B gain, 13q deletion, IGH-FGFR3, IGH-MAF & TP53 deletion |
||
CLL panel: ATM deletion, trisomy 12, 13q deletion & TP53 deletion |
||
|
||
Remarks: |
||
1. Specimen should be sent before 3pm . |
||
2. Please call 3505 3949 for advance booking for all the above tests. |
||
3-5-2018